Assessing WuXi XDC Cayman (SEHK:2268) Valuation After New Akari Therapeutics ADC Partnership

Simply Wall St.

04/10

Akari Therapeutics has entered a partnership with WuXi XDC Cayman (SEHK:2268) to support development of Akari’s PH1 payload and AKTX-101 program for metastatic urothelial cancer, further linking WuXi ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2626016437"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2626016437\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2626016437?lang=zh_CN&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-04-10 12:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626016437","market":"sg","top_or_hot":-1,"title":"Assessing WuXi XDC Cayman (SEHK:2268) Valuation After New Akari Therapeutics ADC Partnership","media":"Simply Wall St.","content":"<div>\n<p>Akari Therapeutics has entered a partnership with WuXi XDC Cayman (SEHK:2268) to support development of Akari’s PH1 payload and AKTX-101 program for metastatic urothelial cancer, further linking WuXi ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/assessing-wuxi-xdc-cayman-sehk2268-valuation-after-new-akari\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing WuXi XDC Cayman (SEHK:2268) Valuation After New Akari Therapeutics ADC Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing WuXi XDC Cayman (SEHK:2268) Valuation After New Akari Therapeutics ADC Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-10 12:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/assessing-wuxi-xdc-cayman-sehk2268-valuation-after-new-akari><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Akari Therapeutics has entered a partnership with WuXi XDC Cayman (SEHK:2268) to support development of Akari’s PH1 payload and AKTX-101 program for metastatic urothelial cancer, further linking WuXi ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/assessing-wuxi-xdc-cayman-sehk2268-valuation-after-new-akari\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02268","symbol_name":"药明合联","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/assessing-wuxi-xdc-cayman-sehk2268-valuation-after-new-akari","article_id":"2626016437","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/assessing-wuxi-xdc-cayman-sehk2268-valuation-after-new-akari","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2626016437","pubTimestamp":1775796908,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Akari Therapeutics has entered a partnership with WuXi XDC Cayman (SEHK:2268) to support development of Akari’s PH1 payload and AKTX-101 program for metastatic urothelial cancer, further linking WuXi XDC to next generation ADC platforms.\nSee our latest analysis for WuXi XDC Cayman.\nInvestors appear to be weighing WuXi XDC’s new ADC partnership against a mixed share price pattern. The 30 day share price return of 3.64% contrasts with a 90 day share price return decline of 13.75% and a 1 year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"02268":"药明合联","BK4080":"零售业房地产投资信托","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","ADC":"艾格里房产","SG9999014674.SGD":"Nikko AM All China Equity A SGD","BK1141":"生命科学工具和服务","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4139":"生物科技","BK4539":"次新股","BK4007":"制药","BK4231":"零售房地产信托","LENZ":"Therapeutics"},"translate_title":"评估与Akari Therapeutics ADC建立新合作伙伴关系后WuXi XDC Cayman(SEHK：2268)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02268":0.9,"LENZ":1.5,"DCF":1,"ADC":1.5},"content_text":"Akari Therapeutics has entered a partnership with WuXi XDC Cayman (SEHK:2268) to support development of Akari’s PH1 payload and AKTX-101 program for metastatic urothelial cancer, further linking WuXi XDC to next generation ADC platforms. See our latest analysis for WuXi XDC Cayman. Investors appear to be weighing WuXi XDC’s new ADC partnership against a mixed share price pattern. The 30 day share price return of 3.64% contrasts with a 90 day share price return decline of 13.75% and a 1 year total shareholder return of 91.69%, which together suggest momentum has cooled recently after a strong run. If you are watching how ADC specialists are being priced, it can also be useful to scan beyond a single name and check out 127 healthcare AI stocks With WuXi XDC trading at HK$61.15 and indicators such as its value score of 3 and quoted intrinsic discount, the key question is whether the recent pullback leaves upside on the table or if the market already reflects future growth. AdvertisementPrice to Earnings of 45.4x: Is It Justified? WuXi XDC currently trades on a P/E of 45.4x, which sits above both the Life Sciences industry average of 39.4x and the peer average of 39.4x, so the market is assigning a premium to the shares at the last close of HK$61.15. The P/E multiple compares the current share price with earnings per share and is a common yardstick for research, development and manufacturing businesses in healthcare because it links what you pay today to current profitability. For WuXi XDC, the higher P/E suggests investors are willing to pay more for each unit of earnings relative to industry and peer benchmarks, even though recent earnings growth of 38.4% over the past year trails its 5 year earnings growth rate of 53.6% per year and did not exceed the wider Life Sciences industry figure of 46.3%. Against an estimated fair P/E of 32.5x from the SWS model, the current 45.4x looks stretched, which indicates the valuation multiple could move closer to that lower level if expectations cool. Explore the SWS fair ratio for WuXi XDC Cayman Result: Price-to-Earnings of 45.4x (OVERVALUED) However, the premium P/E leaves little room for disappointment if earnings or revenue growth of 23.5% and net income growth of 24.4% slow, or if client demand softens. Find out about the key risks to this WuXi XDC Cayman narrative. Another View: Cash Flows Point to a Different Story While the 45.4x P/E makes WuXi XDC look expensive, the SWS DCF model paints a different picture. At HK$61.15, the shares trade about 47.4% below an estimated future cash flow value of HK$116.24, which suggests the market price and cash flow view are pulling in opposite directions. For you, that gap raises a practical question: is the premium earnings multiple at risk of compressing, or is the discount to the DCF estimate hinting at mispriced growth potential that the market has yet to fully factor in? Look into how the SWS DCF model arrives at its fair value. 2268 Discounted Cash Flow as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out WuXi XDC Cayman for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 241 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps With sentiment clearly mixed in the earlier sections, this is the moment to look through the numbers yourself and test whether the rewards justify the current set up. To see what the market is already optimistic about, review the 4 key rewards Looking for more investment ideas? If you only focus on one stock, you risk missing other opportunities, so broaden your watchlist now with a few focused screens built to surface clear ideas.  Spot potential value candidates by reviewing companies flagged as 241 high quality undervalued stocks that may combine quality with a discounted market price. Seek steadier compounding potential by scanning 480 dividend fortresses that prioritize income and consistency in their shareholder returns. Prioritize resilience by checking 298 resilient stocks with low risk scores designed to highlight businesses with lower overall risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if WuXi XDC Cayman might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}